AngioDynamics Q3 EPS Forecast Decreased by Zacks Research

AngioDynamics, Inc. (NASDAQ:ANGO) – Research analysts at Zacks Research cut their Q3 2026 EPS estimates for shares of AngioDynamics in a research report issued to clients and investors on Tuesday, March 25th. Zacks Research analyst D. Dey now forecasts that the medical instruments supplier will post earnings per share of ($0.05) for the quarter, down from their prior forecast of ($0.04). The consensus estimate for AngioDynamics’ current full-year earnings is ($0.37) per share. Zacks Research also issued estimates for AngioDynamics’ Q4 2026 earnings at $0.00 EPS, FY2026 earnings at ($0.28) EPS and FY2027 earnings at ($0.18) EPS.

Separately, HC Wainwright boosted their price target on shares of AngioDynamics from $14.00 to $15.00 and gave the stock a “buy” rating in a research note on Friday, January 10th.

AngioDynamics Trading Down 0.6 %

Shares of ANGO opened at $9.83 on Friday. The firm has a market capitalization of $397.78 million, a P/E ratio of -1.75 and a beta of 0.56. AngioDynamics has a 12-month low of $5.47 and a 12-month high of $13.50. The firm has a 50-day moving average price of $10.47 and a 200 day moving average price of $8.77.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings results on Wednesday, January 8th. The medical instruments supplier reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.07. The company had revenue of $72.90 million during the quarter, compared to analyst estimates of $70.93 million. AngioDynamics had a negative net margin of 79.38% and a negative return on equity of 7.26%. The firm’s revenue was down .1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.05) EPS.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. Systematic Financial Management LP lifted its position in AngioDynamics by 4.6% during the 4th quarter. Systematic Financial Management LP now owns 2,521,065 shares of the medical instruments supplier’s stock worth $23,093,000 after acquiring an additional 110,719 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in AngioDynamics by 10.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,488,667 shares of the medical instruments supplier’s stock worth $13,636,000 after buying an additional 135,007 shares during the last quarter. Segall Bryant & Hamill LLC increased its holdings in shares of AngioDynamics by 55.3% in the 4th quarter. Segall Bryant & Hamill LLC now owns 1,415,156 shares of the medical instruments supplier’s stock worth $12,963,000 after acquiring an additional 503,713 shares during the period. Nuveen Asset Management LLC boosted its position in shares of AngioDynamics by 37.4% during the fourth quarter. Nuveen Asset Management LLC now owns 1,296,366 shares of the medical instruments supplier’s stock worth $11,875,000 after buying an additional 353,070 shares during the period. Finally, Royce & Associates LP boosted its position in AngioDynamics by 13.5% during the 4th quarter. Royce & Associates LP now owns 1,119,385 shares of the medical instruments supplier’s stock worth $10,254,000 after acquiring an additional 133,312 shares during the period. 89.43% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, SVP Warren Nighan, Jr. sold 4,060 shares of the business’s stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $12.31, for a total value of $49,978.60. Following the completion of the transaction, the senior vice president now owns 41,817 shares of the company’s stock, valued at $514,767.27. The trade was a 8.85 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 5.40% of the stock is owned by insiders.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.